You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
强生称部分新冠疫苗原料不符标准 导致疫苗不能使用
阿思达克 04-01 11:49
《美联社》报道,强生(JNJ.US)表示旗下一批新冠疫苗未能达到质量标准,不能使用。公司没有披露受影响疫苗数量。《彭博通讯社》引述消息指,事件涉及1,500万剂疫苗。

公司指,由Emergent BioSolutions(EBS.US)提供的疫苗材料不符合质素标准,且对方亦未获美国食品及药物管理局批准参与新冠疫苗生产。

强生早前承诺上月向美国政府供应2,000万剂疫苗,并於5月完成供应最少8,000万剂。公司目前仍计划在年中前完成交付1亿剂疫苗。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account